WHO Report Shows Increase in HIV Drug Resistance to Dolutegravir

The World Health Organization’s HIV Drug Resistance Report reveals growing drug resistance in populations receiving dolutegravir-containing antiretroviral therapy (ART). However, levels of HIVDR to DTG are exceeding clinical trials. The report recommends dolutegravir as the preferred treatment due to its effectiveness, ease of use, and genetic barrier to resistance. Resistance to dolutegravir ranges from 3.9% to 8.6%, reaching 19.6% among those with high viral loads.